Nadolol: a review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris

Drugs
R C HeelG S Avery

Abstract

Nadolol is a nonselective beta-adrenoceptor blocking drug without intrinsic sympathomimetic or membrane stabilising activity. Its inherently long duration of activity makes it suitable for once daily administration in both hypertension and angina pectoris, and in these conditions it has been as effective as propranolol given in a traditional regimen 4 times daily. However, other beta-blocking drugs can also be given with reduced frequency, especially in hypertension; and some, such as atenolol (a longer acting 'cardioselective' agent) or long-acting preparations of other beta-blockers, have also been given once daily in angina prophylaxis. Nevertheless, nadolol is one of a few beta-blocking drugs which have clearly been shown to be effective in both hypertension and angina with once daily administration. Other specific properties of nadolol, such as its excretion entirely in unmetabolised form, may offer advantages over other existing beta-blocking drugs in specific patients, while some properties (such as lack of 'cardioselectivity') may be disadvantageous in others. The choice of a beta-blocking drug should thus be based on a knowledge of the pharmacodynamic and pharmacokinetic properties of the different beta-blocking drugs,...Continue Reading

Citations

Sep 1, 1991·JPEN. Journal of Parenteral and Enteral Nutrition·W T ChanceJ E Fischer
Jan 1, 1985·European Journal of Clinical Pharmacology·S DeanD A Jackson
Feb 1, 1983·Journal of Clinical Pharmacology·I S CohenS M Hargus
Jun 26, 2001·British Journal of Clinical Pharmacology·A H AbdelmawlaC M Bradshaw
Aug 1, 1987·The Journal of Pharmacy and Pharmacology·K Ichihara, Y Abiko
Jul 1, 1984·Canadian Anaesthetists' Society Journal·D C Chung, M J Laschuk
Jan 1, 1986·The Journal of International Medical Research·R R LutherM J Klepper
Aug 27, 1981·The New England Journal of Medicine·J Koch-Weser, W H Frishman
Sep 17, 1981·The New England Journal of Medicine·W H Frishman
Nov 1, 1986·Journal of Clinical Pharmacology·G LeopoldK U Bühring
Apr 1, 1982·Journal of Clinical Pharmacology·D T O'ConnorK L Duchin
Mar 1, 1987·Acta Physiologica Scandinavica·H Hallberg, O Almgren
Jul 1, 1988·British Journal of Clinical Pharmacology·T H TiongM S Perelman
Nov 1, 1984·Journal of Clinical Pharmacology·G ParkerC J Roberts
Mar 28, 1998·British Journal of Clinical Pharmacology·A H AbdelmawlaC M Bradshaw
Feb 20, 2013·Drug Metabolism and Pharmacokinetics·Nozomu MiyazakiJunko Kimura
Jan 1, 1982·The Journal of International Medical Research·D González
Jan 3, 2021·Journal of Clinical Pharmacology·Sho ShimazakiShingen Misaka
Oct 1, 1984·Annals of Neurology·N L FosterT N Chase
May 1, 1990·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·A Gatta, C Merkel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.